Evotec

Evotec is appointing Joanna Holbrook to the executive board and as chief scientific officer effective 1 November 2026; she brings more than 25 years of experience in omics, data sciences, novel therapeutics and precision medicine. Holbrook joins from Novo Nordisk, where she served, among other roles, as therapy area head for cardiovascular, renal and liver diseases and as head of in vitro discovery platforms. The appointment supported the stock in the short term, but for a sustainable turnaround Evotec must clearly improve profitability. » Mere på deraktionaer.de

Evotec reports revenue of 465.0 million euros and an adjusted negative EBITDA of 42.8 million euros for the first nine months, both better than analysts had expected. The management board leaves the July-lowered full-year guidance unchanged at 570–610 million euros in revenue and an adjusted EBITDA of -70 to -105 million euros. The share price rose by nearly seven percent after the figures, but remains substantially down year-to-date. » Mere på finanzen.net

Evotec stands by the annual forecast it lowered in mid‑July and expects revenue of €570 to €610 million. Adjusted EBITDA is forecast at between minus €70 million and minus €105 million. For the first nine months the company expects revenue of €465.0 million and adjusted EBITDA of minus €42.8 million, which is above current market expectations and is mainly attributed to the timing of consensus estimates. » Mere på finanzen.net